Tredje AP fonden Trims Position in AbbVie Inc. (NYSE:ABBV)
Tredje AP fonden Trims Position in AbbVie Inc. (NYSE:ABBV)
Tredje AP fonden decreased its position in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 0.5% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 412,491 shares of the company's stock after selling 2,000 shares during the period. AbbVie accounts for approximately 1.4% of Tredje AP fonden's portfolio, making the stock its 12th largest holding. Tredje AP fonden's holdings in AbbVie were worth $66,869,000 at the end of the most recent quarter.
根据美联社最近向美国证券交易委员会披露的信息，美联社在第一季度减持了艾伯维公司的股票头寸0.5%。在此期间出售了2,000股后，该公司持有该公司412,491股股票。AbbVie约占Tredje AP Fonden投资组合的1.4%，使该股成为其第12大持股。截至最近一个季度末，Tredje AP Fonden在AbbVie持有的股份价值66,869,000美元。
Other institutional investors and hedge funds have also modified their holdings of the company. Summit Asset Management LLC grew its holdings in AbbVie by 6.2% during the 1st quarter. Summit Asset Management LLC now owns 4,459 shares of the company's stock valued at $723,000 after purchasing an additional 259 shares in the last quarter. Tectonic Advisors LLC boosted its stake in AbbVie by 14.5% during the 1st quarter. Tectonic Advisors LLC now owns 9,146 shares of the company's stock valued at $1,483,000 after acquiring an additional 1,161 shares during the last quarter. Proffitt & Goodson Inc. boosted its stake in AbbVie by 34.6% during the 1st quarter. Proffitt & Goodson Inc. now owns 1,191 shares of the company's stock valued at $193,000 after acquiring an additional 306 shares during the last quarter. Banque Cantonale Vaudoise lifted its position in shares of AbbVie by 8.6% in the 1st quarter. Banque Cantonale Vaudoise now owns 59,133 shares of the company's stock worth $9,584,000 after buying an additional 4,667 shares during the last quarter. Finally, Capital Square LLC bought a new position in shares of AbbVie in the 1st quarter worth about $227,000. Hedge funds and other institutional investors own 67.03% of the company's stock.
其他机构投资者和对冲基金也调整了对该公司的持股。Summit Asset Management LLC在第一季度增持了6.2%的AbbVie股份。Summit Asset Management LLC现在拥有4459股该公司股票，价值72.3万美元，上个季度又购买了259股。Structure Advisors LLC在第一季度将其在AbbVie的持股增加了14.5%。Structure Advisors LLC现在拥有该公司9,146股股票，价值1,483,000美元，在上个季度又购买了1,161股。Proffitt&Goodson Inc.在第一季度将其在AbbVie的持股增加了34.6%。Proffitt&Goodson Inc.在上个季度增持了306股后，现在持有1,191股该公司股票，价值19.3万美元。第一季度，Canonale Vaudoise银行将其在AbbVie股票的头寸提高了8.6%。Canonale Vaudoise银行现在拥有59,133股该公司股票，价值9,584,000美元，在上个季度又购买了4,667股。最后，Capital Square LLC在第一季度购买了价值约22.7万美元的AbbVie新股票头寸。对冲基金和其他机构投资者持有该公司67.03%的股份。
AbbVie Stock Up 0.2 %
AbbVie股价上涨0.2%
NYSE ABBV traded up $0.25 during trading hours on Friday, reaching $139.17. 83,173 shares of the company's stock were exchanged, compared to its average volume of 6,025,083. The company's 50-day moving average is $147.75 and its two-hundred day moving average is $150.05. AbbVie Inc. has a one year low of $105.56 and a one year high of $175.91. The company has a debt-to-equity ratio of 3.89, a quick ratio of 0.71 and a current ratio of 0.82. The company has a market capitalization of $245.93 billion, a price-to-earnings ratio of 19.68, a price-to-earnings-growth ratio of 3.96 and a beta of 0.70.
纽约证券交易所ABBV在周五的交易时间里上涨了0.25美元，达到139.17美元。该公司股票成交量为83,173股，而其平均成交量为6,025,083股。该公司50日移动均线切入位在147.75美元，200日移动均线切入位在150.05美元。AbbVie Inc.的一年低点为105.56美元，一年高位为175.91美元。该公司的负债权益比率为3.89，速动比率为0.71，流动比率为0.82。该公司市值2,459.3亿美元，市盈率19.68倍，市盈率3.96倍，贝塔系数0.70。
AbbVie Announces Dividend
AbbVie宣布分红
The business also recently declared a quarterly dividend, which will be paid on Monday, August 15th. Investors of record on Friday, July 15th will be given a $1.41 dividend. This represents a $5.64 dividend on an annualized basis and a dividend yield of 4.05%. The ex-dividend date is Thursday, July 14th. AbbVie's payout ratio is currently 79.89%.
该公司最近还宣布了季度股息，将于8月15日(星期一)支付。7月15日(星期五)登记在册的投资者将获得1.41美元的股息。这意味着年化股息为5.64美元，股息收益率为4.05%。除股息日期为7月14日星期四。AbbVie的派息率目前为79.89%。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several equities analysts have commented on the stock. Piper Sandler lowered their target price on shares of AbbVie from $160.00 to $155.00 in a research note on Friday, July 29th. Barclays raised their target price on shares of AbbVie from $150.00 to $174.00 and gave the stock an "equal weight" rating in a report on Tuesday, April 12th. SVB Leerink started coverage on shares of AbbVie in a report on Monday, May 23rd. They set an "underperform" rating and a $140.00 price target for the company. UBS Group reduced their target price on shares of AbbVie from $154.00 to $146.00 and set a "neutral" rating for the company in a research note on Monday. Finally, The Goldman Sachs Group lifted their target price on shares of AbbVie from $122.00 to $140.00 and gave the company a "neutral" rating in a research note on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $159.29.
几位股票分析师对该股发表了评论。派珀·桑德勒在7月29日星期五的一份研究报告中将艾伯维的目标股价从160.00美元下调至155.00美元。巴克莱将艾伯维股票的目标价从150.00美元上调至174.00美元，并在周二的一份报告中给予该股“同等权重”的评级。SVB Leerink在5月23日星期一的一份报告中开始报道AbbVie的股票。他们为该公司设定了“表现不佳”的评级和140.00美元的目标价。瑞银集团周一在一份研究报告中将艾伯维股票的目标价从154.00美元下调至146.00美元，并将该公司的评级定为“中性”。最终，高盛夫妇将艾伯维股票的目标价从122.00美元上调至140.00美元，并在周二的一份研究报告中给出了该公司“中性”的评级。一名投资分析师对该股的评级为卖出，6名分析师给予持有评级，10名分析师给予买入评级，一名分析师给予该公司强烈买入评级。根据MarketBeat的数据，该公司目前的平均评级为“中等买入”，平均目标价为159.29美元。
Insider Activity at AbbVie
艾伯维的内幕活动
In other news, Vice Chairman Michael Severino sold 100,000 shares of AbbVie stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $154.45, for a total transaction of $15,445,000.00. Following the sale, the insider now directly owns 152,103 shares of the company's stock, valued at $23,492,308.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other AbbVie news, EVP Henry O. Gosebruch sold 83,960 shares of the firm's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $155.00, for a total value of $13,013,800.00. Following the transaction, the executive vice president now directly owns 16,623 shares of the company's stock, valued at $2,576,565. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Vice Chairman Michael Severino sold 100,000 shares of the firm's stock in a transaction on Monday, May 16th. The shares were sold at an average price of $154.45, for a total transaction of $15,445,000.00. Following the completion of the transaction, the insider now directly owns 152,103 shares in the company, valued at $23,492,308.35. The disclosure for this sale can be found here. Insiders have sold 363,761 shares of company stock valued at $55,528,771 over the last ninety days. 0.08% of the stock is owned by corporate insiders.
在其他新闻方面，副董事长迈克尔·塞维里诺在5月16日星期一的交易中出售了10万股AbbVie股票。股票以154.45美元的平均价格出售，总成交金额为15,445,000.00美元。出售后，这位内部人士现在直接拥有152,103股该公司股票，价值23,492,308.35美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可通过美国证券交易委员会网站访问。在AbbVie的其他新闻中，执行副总裁Henry O.Gosebruch在5月16日星期一的一笔交易中出售了83,960股公司股票。这些股票的平均价格为155.00美元，总价值为13,013,800.00美元。交易完成后，执行副总裁总裁现在直接持有该公司16,623股股票，价值2576,565美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，可以通过以下链接访问该文件。此外，副董事长迈克尔·塞维里诺在5月16日星期一的一次交易中出售了10万股该公司的股票。这些股票以154.45美元的平均价格出售，总成交金额为15,445,000.00美元。交易完成后，这位内部人士现在直接拥有该公司152,103股，价值23,492,308.35美元。此次拍卖的披露信息可在此处找到。在过去的90天里，内部人士已经出售了363,761股公司股票，价值55,528,771美元。0.08%的股份由企业内部人士持有。
AbbVie Profile
AbbVie个人资料
(Get Rating)
(获取评级)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
艾伯维公司在世界各地发现、开发、制造和销售药品。该公司提供HUMIRA，用于注射治疗自身免疫和肠道Behçet‘s疾病；SKYRIZI用于治疗成人中到重度斑块型牛皮癣；RINVOQ，用于治疗成人患者的中到重度活动性类风湿性关节炎；IMBRUVICA，用于治疗成人慢性淋巴细胞白血病和小淋巴细胞淋巴瘤；以及VENCLEXTA，用于治疗成人慢性丙型肝炎病毒基因1-6感染。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on AbbVie (ABBV)
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- BJ's Wholesale Club Stock Has More Room to Grow
- 3 Hotel Stocks to Consider Checking into After Earnings
- 免费获取StockNews.com关于AbbVie的研究报告(ABBV)
- 克罗诺斯集团(Cronos Group Inc.)营收上升，是时候收购了吗？
- 苹果为何可能在年底创下历史新高
- Beyond Meat不是没有希望，而且它很便宜
- 北京批发俱乐部库存有更大的增长空间
- 盈利后考虑登记的3家酒店股票
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
接收AbbVie Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对AbbVie和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。